From owner-recombination@net.bio.net Sun Oct 03 15:19:00 1999 Path: biosci!biosci!not-for-mail From: "Dr. Mark Chance" Newsgroups: bionet.molbio.recombination Subject: Research Scientist Position Date: 3 Oct 1999 09:19:40 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 43 Sender: daemon@net.bio.net Approved: genestructure@yahoo.com Distribution: world Message-ID: <7t7vms$jck@net.bio.net> NNTP-Posting-Host: net.bio.net ---------------------------------------------------------- Mark R. Chance, Albert Einstein College of Medicine Center for Synchrotron Biosciences, An NIH Shared Resource Ullman 315, Department of Physiology & Biophysics 1300 Morris Park Ave., Bronx NY 10461 ph. 718-430-4136; fax-718-430-8587; internet : mrc@aecom.yu.edu http://beam.aecom.yu.edu/Phys&bio/csb1.htm ********************************************* Mark R. Chance, Professor of Physiology & Biophysics and Biochemistry and Director, Albert Einstein Center for Synchrotron Biosciences, An NIH Resource Center Albert Einstein College of Medicine Ullmann 315, Department of Physiology & Biophysics 1300 Morris Park Ave., Bronx NY 10461 ph. 718-430-4136; fax-718-430-8587; internet : mrc@aecom.yu.edu http://beam.aecom.yu.edu/Phys&bio/csb1.htm Also National Synchrotron Light Source, Brookhaven National Labs Building 725A-X9 Upton NY 11973 ph: 516-344-3800; fax-516-344-5594 ********************************************* ===== Moderated bionet.genome.gene-structure __________________________________________________ Do You Yahoo!? Bid and sell for free at http://auctions.yahoo.com From owner-recombination@net.bio.net Tue Oct 12 19:16:00 1999 Path: biosci!biosci!not-for-mail From: eveljkve@ubbg.etf.bg.ac.yu (Veljko Veljkovic) Newsgroups: bionet.molbio.recombination Subject: HIV recombination and dangers of AIDS Date: 12 Oct 1999 13:16:44 -0700 Organization: MRC Human Genome Mapping Project Lines: 304 Sender: daemon@net.bio.net Approved: genestructure@yahoo.com Distribution: world Message-ID: <7u04vc$l55@net.bio.net> NNTP-Posting-Host: net.bio.net Dear Colleges, For most researchers working on the AIDS problem it is clear that HIV represents a necessary but not sufficient condition for AIDS. This is the reason why it is harmful to reject it as a causative agent of AIDS. But also it is not less harmful to accept the current rigid and oversimplified view on its role in AIDS, which resulted in a wrong and dangerous therapy and irreparable loss of precious time in fight with the AIDS epidemic. I would like to draw your attention to another important aspect of this problem. According to our decade long research a significant factor in AIDS pathogenesis represents a recombination between HIV and coinfecting pathogens, endogenous retroviruses, as well as the host genes. This process allows HIV to evolve fast, resulting in avoidance of an effective immune response and the multypathway attack on the host immune and neuronal system. The key player in this game is the gene encoding HIV envelope glycoprotein gp120. Unfortunately, existing genotoxic therapy stimulates this process and as result of this therapy we have today in circulation new resistant and more aggressive HIV strains. What is even worse, existing AIDS vaccine candidates are based on the viral vectors carrying the HIV-1 envelope gen. Viruses modified in this way represent possible prone for recombination with the endemic pathogens which could result in generation of a new chimeric pathogens (currently hundreds of people in Uganda are vaccinated with the canarypox virus carrying the recombinogenic HIV-1 gp120 gene with risk of new epidemic initiated by recombination between the vaccine vector and the endemic viruses (Ebola, monkeypox and Marborg). In three papers which we have published this year in the peer-reviewed journals we have strongly confirmed this possibility demonstrating that (1) HIV can recombine in vivo with coinfecting bacteria forming chimeric quasispecies, and (2) that normal HIV-negative sera contains antibodies reacting with principal neutralizing antigenic region within HIV-1 V3 loop. It is absurd that people should be alarmed about genetically modified food and that nobody should pay any attention to the vaccination of thousands people with recombinant viral vectors carrying the most dangerous HIV component representing a potential source of new infectious diseases with unpredictable influence on the human population. I am enclosing my letter concerning this problem which I have sent to WHO and NIH a year ago. More details about the AIDS vaccine problem, as well as my nearly decade long correspondence with the key people from WHO and NIH containing arguments from both sides concerning this problem can be found on the Internet address www.newstrolls.com. I am inviting all colleges to contribute by "pro at contra" arguments to the solution of this important problem. Veljko Veljkovic References 1.. Prljic J., Veljkovic N., Doliana R., Colombatti A., Johnson E., Metlas R., Veljkovic V. Identification of an complete and active recombinational hot spot within the HIV-1 gp120 gene: possible implications for the AIDS vaccine development. Vaccine, Vol. 17, 1462 (1999). 2. Metlas R., Trajkovic D., Srdic T., Veljkovic V., Colombatti A. Human immunodeficency virus V3 peptide-reactive antibodies are present in normal HIV-negative sera. AIDS Res. Hum. Retrovir., Vol. 15, 671 (1999). 3. Metlas R., Trajkovic D. Srdic T., Veljkovic V. Colombatti A. Anti-V3 and anti-IgG antibodies of healthy individuals Share complementarity structurers. J. Acquir. Immune. Defic. Sindr., Vol. 21, 266 (1999). The WHO/NIH letter Dr. Hirosi Nakajima Dr. Harold Varmus Director general NIH Director Headquarters Office Office of the Director World Health Organisation National Institutes of Health (NIH) Avenue Appia 20 Bethesda, Maryland 20802 1211 Geneva 27 October 16, 1998 Dear Dr. Nakajima/Varmus, The CDC announced on October 6, 1998, that new drugs helped reduced the number of AIDS deaths by 47 percent last year in the US, dropping the disease from the 10 leading causes of death. The information concerning this transient success, transmitted by the press agencies worldwide, could erroneously lead to the wrong conclusion that we are close to controlling AIDS, transforming it from an acute to a chronic disease. Scientists of course should know that the reality is completely different. In the first half of this year the following has been reported: (1) the appearance of an infective HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors, in other words resistant to all known effective antiretroviral therapy [Hecht et al., New Engl. J. Med. 339: 307 (1998)], (2) identification of a new HIV-1 subtype distinct from other known subtypes, which escapes detection by all currently employed HIV tests [Simon et al., Nature Med. 4: 1032 (1998)], (3) the finding that one of the most promising AIDS vaccine candidates prepared for clinical trials may in fact cause AIDS [Ruprecht et al., Proc. 12th World AIDS Conf. 1998, Art. 608], and (4) that atypical transmission of HIV may occur, meaning that the virus can spread through populations with no identified risk factor for transmission [Belec et al., J. Virol. 72: 5831 (1998)]. Behind all of these events, reminding us of the tragic fact that the 14 year battle against AIDS has definitely not been won, is the evolution of variation in HIV. Worse still, the current development and testing of AIDS vaccines appears to accelerate this unpredictable, uncontrollable and thus dangerous process of viral genetic variation. Seven years ago in our letters to WHO and NIH, the two most responsible organizations for AIDS vaccine development, we explained the potentially negative effects of AIDS vaccines based on the HIV-1 gp120/160, suggesting that from both practical and especially ethical reasons, decisions concerning the conduction of clinical trials of these vaccines, should be carefully reexamined (see enclosed the substantive text of this demand which was published in Vaccine, enclosure 1). Possible harmful effects of such an AIDS vaccine could be summarized as follows: (1) it could make vaccinees more vulnerable to HIV infection, and (2) it could generate new pathogens with unpredictable effects on the human immune and neuronal system (molecular basis of these negative effects is given in the enclosed paper, enclosure 2). Unfortunately, key people from the WHO and NIH which are responsible for development of AIDS vaccines, although alerted to this risk, ignored it, often using baffeling and scientifically unacceptable arguments (see the enclosed correspondence, enclosure 3). Our recent experiments have confirmed in vivo recombination between HIV-1 and coinfecting bacteria (see the enclosed article which is in print, enclosure 4). These results confirmed the possibility of generation of chimeric pathogens representing a natural recombination between HIV and coinfecting bacterial and viral pathogens. The recently reported spread in the US and elsewhere of the chimeric form of Mycoplasma fermentas carrying the HIV-1 gp120 gene which has been implicated in the Golf war syndrome [Nicolson at al., Int. J. Medicine, 1, 80-92 (1998)], definitely confirmed that chimeric recombination between bacteria and HIV can represent stabile and extremely infectious pathogens which spread very fast through populations. These facts strongly emphasize that, despite the urgent need for preventive AIDS vaccines, it would be wise to introduce a moratorium on clinical trials until there is a serious reexamination of the current concepts for their development. Furthermore, such vaccines could become the source of potentially new infectious diseases rather than an effective instrument for AIDS prevention. Unfortunately, researchers worldwide, supported by WHO and NIH, despite this risk continue developing and testing AIDS vaccines using as vectors different very contagious viruses and bacteria. I hope that the WHO and NIH, as the two most responsible organizations, will seriously reflect on this problem and consider a moratorium on further uncontrolled development and laboratory testing of recombinant viral and bacterial vectors carrying HIV genes, as well as premature clinical testing of AIDS vaccines which, without complete knowledge of the biological and immunological properties of HIV, could produce irreparable and irreversible long term consequences. Sincerely yours, Veljko Veljkovic --- ===== Moderated bionet.genome.gene-structure __________________________________________________ Do You Yahoo!? Bid and sell for free at http://auctions.yahoo.com From owner-recombination@net.bio.net Tue Oct 12 19:18:00 1999 Path: biosci!biosci!not-for-mail From: cweil@uidaho.edu (Clifford Weil) Newsgroups: bionet.molbio.recombination Subject: Graduate Student Assistantship Date: 12 Oct 1999 13:18:13 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 31 Sender: daemon@net.bio.net Approved: genestructure@yahoo.com Distribution: world Message-ID: <7u0525$les@net.bio.net> NNTP-Posting-Host: net.bio.net cweil@uidaho.edu or to : Clifford Weil Dept. of Biological Sciences University of Idaho Moscow, ID 83844-3051 Clifford Weil Associate Professor Dept. of Biological Sciences Univ. of Idaho Moscow, ID 83844-3051 USA Tel: 208-885-6370 Fax: 208-885-7905 ===== Moderated bionet.genome.gene-structure __________________________________________________ Do You Yahoo!? Bid and sell for free at http://auctions.yahoo.com From owner-recombination@net.bio.net Fri Oct 15 07:47:00 1999 Path: biosci!biosci!not-for-mail From: "Mike Briley" Newsgroups: bionet.molbio.recombination Subject: Symposium on Molecular Genetics in Mental Date: 15 Oct 1999 01:46:58 -0700 Organization: ImagiNET Lines: 27 Sender: daemon@net.bio.net Approved: genestructure@yahoo.com Distribution: world Message-ID: <7u6pm2$f2k@net.bio.net> NNTP-Posting-Host: net.bio.net There is still time (just) to register for the Symposium on Molecular Genetics in Mental Disorders that will take place in Castres, France 1-3 December 1999. Full details (including registration forms) are available from http://www.entretiens-du-carla.com Mike Briley ===== Moderated bionet.genome.gene-structure __________________________________________________ Do You Yahoo!? Bid and sell for free at http://auctions.yahoo.com From owner-recombination@net.bio.net Fri Oct 15 07:47:00 1999 Path: biosci!biosci!not-for-mail From: cweil@uidaho.edu (Clifford Weil) Newsgroups: bionet.molbio.recombination Subject: Graduate Student Assistantship Date: 15 Oct 1999 01:46:58 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 46 Sender: daemon@net.bio.net Approved: genestructure@yahoo.com Distribution: world Message-ID: <7u6pm2$f2n@net.bio.net> NNTP-Posting-Host: net.bio.net Available immediately, one graduate research assistantship at the University of Idaho, to study DNA repair in plants. The project involves using Ac/Ds transposons and the damage caused when they excise to look at plant DNA repair of the excision sites (see Plant J. 12:1419-1428(1997)). Work will involve use of DNA constructs introduced and recovered from plant cells to examine DNA damage and repair during transposon excision and analysis of Ac/Ds transposition in yeast cells. The degree is through the Molecular Biology Dept. graduate program, and the compensation package starts at $16,100. Please send letter of interest, CV (including GRE scores and description of previous lab experience) and the names of three references, either to cweil@uidaho.edu or to : Clifford Weil Dept. of Biological Sciences University of Idaho Moscow, ID 83844-3051 Clifford Weil Associate Professor Dept. of Biological Sciences Univ. of Idaho Moscow, ID 83844-3051 USA Tel: 208-885-6370 Fax: 208-885-7905 ===== Moderated bionet.genome.gene-structure __________________________________________________ Do You Yahoo!? Bid and sell for free at http://auctions.yahoo.com From owner-recombination@net.bio.net Fri Oct 15 07:51:00 1999 Path: biosci!biosci!not-for-mail From: BIOSCI Administrator Newsgroups: bionet.molbio.recombination Subject: BIOSCI/bionet miniFAQ & Fundraiser Date: 15 Oct 1999 01:51:11 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 389 Sender: daemon@net.bio.net Approved: genestructure@yahoo.com Distribution: world Message-ID: <7u6ptv$g2i@net.bio.net> NNTP-Posting-Host: net.bio.net (LAST REVISION: 14-AUG-99) This BIOSCI "miniFAQ" is designed to answer the questions that come up the *most frequently*. The main BIOSCI FAQ (Frequently Asked Questions) is accessible on the World Wide Web at URL http://www.bio.net/. If you can not find an answer to your question in this or other documentation, the BIOSCI technical support staff answers e-mail queries sent to biosci-help@net.bio.net We can only answer questions about the use of the newsgroups and mailing lists. We unfortunately do not have the staff to do Internet information searches or answer scientific questions. Please post those to the appropriate BIOSCI/bionet newsgroups. Contents: -------- 0) BIOSCI NEEDS YOUR SUPPORT!! 1) Using the WWW to access the BIOSCI/bionet newsgroups. 2) What to do about "spams," i.e., junk mail, ads, etc. 3) Examples of subscribing and unsubscribing to the mailing lists. 4) The BIOSCI user address and research interest directory. 0) BIOSCI NEEDS YOUR SUPPORT!! ------------------------------ BIOSCI's government funding has been expended, and we are now operating solely from advertising revenue that we have raised from our Web site at http://www.bio.net/. We need just a few minutes of your time to help us serve you. You can do two important things which will take very little time for you individually and will immensely help us continue to help you. First, please use our WWW system at http://www.bio.net/ to access the archives. You can post or reply to messages via your Web browser as described in item #1 below. Your usage helps attract sponsors. If you contact any of our sponsors, please be sure to thank them for supporting BIOSCI. It is critical for them to get this feedback if they are to continue their sponsorship for the long term. Second, if you work for a company or organization that provides products or services of interest to the biology community, please pass this message on to your marketing or marketing communications department or other appropriate group. Please ask them to help support BIOSCI by sponsoring our Web site and explain the uses and benefits of the system to the biology community. If they are interested, they can then contact us for further information at our tech support address, biosci-help@net.bio.net. 1) Using the WWW to access the BIOSCI/bionet newsgroups. -------------------------------------------------------- All BIOSCI/bionet full newsgroups are accessible through the World Wide Web (WWW) at URL http://www.bio.net. One can read and reply publicly or privately to both recent postings and archived messages through one's Web browser if it is configured properly to send e-mail. Each newsgroup is equipped with its own WAIS index. The main BIOSCI home page also has access to the BIO-JOURNALS Table of Contents database WAIS index and the BIOSCI user address database described in another item further below. 2) What to do about "spams," i.e., junk mail, ads, etc. ------------------------------------------------------- BIOSCI is a set of parallel USENET newsgroups (the "bionet" groups), mailing lists, and a hypermail archive at URL http://www.bio.net/. The same postings are distributed on all media (except for a small number of mailing-list-only groups at net.bio.net). Unfortunately it is becoming a despicable practice on the Internet (by a few people out to make a fast buck) to do automated mass postings to thousands of newsgroups and mailing lists. These attempts to grab free advertising are refered to as "spams" in the usual, somewhat boneheaded, net terminology. USENET is more susceptible to this practice, and many spams originate on the USENET groups and then are passed on to the mailing lists. However, spammers also get lists of mailing addresses and hit these too, so neither medium is immune. What should you do personally if you get junk mail? --------------------------------------------------- Just delete it and move on without reading it further. Filing a protest is becoming increasingly useless because spammers are often disguising the addresses where the messages are sent from. Unless you really understand Internet mail systems, your attempt at protest by sending replies to the message will often end up being sent to the address of an innocent person that the spammer is victimizing. What can BIOSCI/bionet do to protect its newsgroups? ---------------------------------------------------- The only solution currently available is to moderate the newsgroup. If this newsgroup is already moderated, then you are in good shape. Moderation protects the USENET distribution from about 95% of the spams that are being sent to date and protects the mailing lists completely. Moderation means, however, that someone has to take the time to review each message before it goes out. We have set up software here that simply allows the moderator to forward to an address at net.bio.net messages that (s)he wishes to have distributed. This takes no more time than that needed to read the message and pass it on, say about 1 min. per message. Most newsgroups currently have a discussion leader who is responsible for their newsgroup. The discussions leaders and their e-mail addresses are listed in the BIOSCI Information Sheet which is available on the Web at http://www.bio.net/. If a newsgroup is being hit with too many junk postings, please contact the discussion leader for that group and see if there is interest in moderating the group. Please do not assume that by simply posting a complaint to the newsgroup itself, anyone on the BIOSCI staff will act on your complaint. With close to 100 newsgroups to run, the BIOSCI staff has to rely on the discussion leaders of each newsgroup to report problems directly to us at biosci-help@net.bio.net. We will moderate any of our newsgroups if the discussion leader tells us that the readership of the group wishes to do so and if a moderator is willing to do the work. For most BIOSCI/bionet groups, this entails only a few minutes of work each day. Moderating a newsgroup will resolve probably 95% of the junk postings on the USENET distribution. Unfortunately there are easy ways for determined spammers to override the moderation mechanism on USENET, but we can protect our e-mail subscribers from unwanted postings if the newsgroup is moderated. You can also access our newsgroups over the WWW at URL http://www.bio.net. While this Web interface will not stop spammers from trying to post to the groups, this will give you yet another way, besides using USENET news, to keep the junk out of your personal mail files. For those of you with local USENET news systems, the Web interface will also give you faster access to new newsgroups and recent postings. 3) Examples of subscribing and unsubscribing to the mailing lists. ------------------------------------------------------------------ PLEASE NOTE: The BIOSCI management does NOT act on subscription/unsubscription requests that are posted improperly to the newsgroups and mailing lists. People who do this only bother everyone on the lists to no avail. Please be sure to follow the proper procedures below. Gory details are in the BIOSCI Information sheets on the Web at http://www.bio.net. Below we give an example utilizing the METHODS-AND-REAGENTS list at both of our two BIOSCI sites: Users in the Americas and Pacific Rim countries who use the BIOSCI ------------------------------------------------------------------ node at computer net.bio.net: ---------------------------- A) Determine the "listname" which is the <=8 character mail address ^^^^^^^^^^^^^ for the group. These can be found in the BIOSCI Info. Sheet. For the METHODS-AND-REAGENTS group the mailing address is methods@net.bio.net. The listname is the portion of the address to the left of the @ sign, i.e., "methods". The listname is used with the "subscribe" and "unsubscribe" commands illustrated below. B) Mail all commands in the body of a mail message addressed to biosci-server@net.bio.net. Do NOT send commands to the newsgroup posting addresses! Leave the Subject: line blank, any text on it will be ignored. C) In the body of your message put one or more of the following commands with an "end" command on the last line, e.g., subscribe methods unsubscribe methods end Do NOT put your e-mail address or other text on these lines. The server only allows you to cancel your subscription if the address on your mail header matches the address on our mailing list. Please ask for help at biosci-help@net.bio.net if your address has changed, e.g., if you know you are on the list but the server tells you that you are not a member. Users in Europe, Africa, and Central Asia who use the BIOSCI node at -------------------------------------------------------------------- the UK-HGMP-Resource Centre (known as hgmp.mrc.ac.uk): ----------------------------------------------------- A) Determine the "listname" which is the <=8 character mail address ^^^^^^^^^^^^^ for the group. These can be found in the BIOSCI Info. Sheet. For the METHODS-AND-REAGENTS group the mailing address is methods@hgmp.mrc.ac.uk. The listname is the portion of the address to the left of the @ sign, i.e., "methods". The listname is used with the "subscribe" and "unsubscribe" commands illustrated below. B) Mail all commands in the body of a mail message addressed to majordomo@hgmp.mrc.ac.uk. Do NOT send commands to the newsgroup posting addresses! Leave the Subject: line blank, any text on it will be ignored. C) In the body of your message put one or more of the following commands with an "end" command on the last line, e.g., subscribe methods unsubscribe methods end Please ask for help at biosci@hgmp.mrc.ac.uk if your address has changed, e.g., if you know you are on the list but the server tells you that you are not a member. 4) The BIOSCI user address and research interest directory. ----------------------------------------------------------- Please take this opportunity to add your name, address, and research interest information to the BIOSCI User Address Database if you have not already done so. You can fill out the address form directly through our Web page at URL http://www.bio.net/adrform.html. The address database is reindexed nightly for WWW access (the URL is http://www.bio.net/). If you are not directly on the Internet but can reach it by e-mail, please use our waismail server to access the user directory. waismail use is described above. You can also request a user address form by e-mail from biosci-help@net.bio.net. Please check your database entry from time-to-time to see if your address information is still up-to-date. Because of our limited personnel resources, we ask that you resubmit a *complete* form to revise your entry; we only replace complete entries and do not have resources to edit old forms. ===== Moderated bionet.genome.gene-structure __________________________________________________ Do You Yahoo!? Bid and sell for free at http://auctions.yahoo.com From owner-recombination@net.bio.net Sun Oct 17 21:55:00 1999 Path: biosci!biosci!not-for-mail From: Sripathi Ramadurai Newsgroups: bionet.molbio.recombination Subject: Linkage Disequilibrium Date: 17 Oct 1999 15:55:14 -0700 Organization: @home Lines: 21 Sender: daemon@net.bio.net Approved: genestructure@yahoo.com Distribution: world Message-ID: <7udk4i$reb@net.bio.net> NNTP-Posting-Host: net.bio.net Could somebody please explain to me what 'Linkage Disequilibrium' is all about? All help is appreciated. Thanks, Sri > ===== Moderated bionet.genome.gene-structure __________________________________________________ Do You Yahoo!? Bid and sell for free at http://auctions.yahoo.com From owner-recombination@net.bio.net Fri Oct 22 07:28:00 1999 Path: biosci!biosci!not-for-mail From: David Humair Newsgroups: bionet.molbio.recombination Subject: DNA shuffling Date: 22 Oct 1999 01:28:57 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 32 Sender: daemon@net.bio.net Approved: genestructure@yahoo.com Distribution: world Message-ID: <7up789$g52@net.bio.net> NNTP-Posting-Host: net.bio.net Hi folks, I want to know more about the technique of DNA shuffling. Do you have any indications of the technical aspects and the reasons why reaserchers do that... Thank you very much David Humair ---------- "Tell a man there are 400 billion stars and he'll believe you; tell him a bench has wet paint and he has to touch it." ---------- ===== Moderated bionet.genome.gene-structure __________________________________________________ Do You Yahoo!? Bid and sell for free at http://auctions.yahoo.com From owner-recombination@net.bio.net Tue Oct 26 09:56:00 1999 Path: biosci!biosci!not-for-mail From: biosoftware@genamics.com Newsgroups: bionet.molbio.recombination Subject: Software for Science 19534 Date: 26 Oct 1999 03:56:47 -0700 Organization: SoftwareSeek Lines: 35 Sender: daemon@net.bio.net Approved: genestructure@yahoo.com Distribution: world Message-ID: <7v41df$4k0@net.bio.net> NNTP-Posting-Host: net.bio.net GENAMICS SOFTWARESEEK The Largest Science Software Directory on Earth. http://genamics.com/software/ Genamics SoftwareSeek now indexes well over 1000 freely-distributable and commercial titles. Classifications include DNA sequence analysis, protein structure analysis, RNA structure prediction, molecular modeling, image analysis, and sequence alignment. All major platforms are supported, including, Windows, Macintosh, Unix, and Linux. Over 150 online tools and resources that run directly through your internet browser are also listed. New software can be submitted on-line through our web-site. Marcel Dinger, Genamics. http://genamics.com/software/ ===== Moderated bionet.genome.gene-structure __________________________________________________ Do You Yahoo!? Bid and sell for free at http://auctions.yahoo.com